CJColleen Jodarski

Colleen Jodarski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Colleen Jodarski has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Armin Raznahan

    National Institute of Mental Health, National Institutes of Health, Bethesda, USA

    2 shared publications
  • Erin Torres

    National Institute of Mental Health, National Institutes of Health, Bethesda, USA

    2 shared publications
  • Morgan Similuk

    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA

    2 shared publications
  • Rachel Gore Moses

    Centralized Sequencing Program National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda Maryland USA

    2 shared publications
  • Rylee Duncan

    National Institute of Mental Health, National Institutes of Health, Bethesda, USA

    2 shared publications
  • Aaron L. Misakian

    Department of Pediatrics, Division of Endocrinology, Stanford School of Medicine, Stanford, CA 94305, USA

    1 shared publication

Latest Publications

  • Open Access

    Functional Characterization of Glucokinase Variants to Aid Clinical Interpretation of Monogenic Diabetes

    by Varsha Rajesh, Dora Evelyn Ibarra, Jing Yang, Haichen Zhang, Amy Barrett, Eleanor G. Kaplan, Amit Kumthekar, Fanny Sunden, Han Sun, Ananta Addala, et al.

    Precision medicine starts with a precision diagnosis. Yet up to 80% of cases of monogenic diabetes, a form of diabetes characterized by mutations in a single gene, are either overlooked or misdiagnosed. A genetic test for monogenic diabetes does not always lead to a precise diagnosis, as novel variants are often classified as variants of unknown significance. Variant interpretation requires collation of a framework of evidence, including population, computational, and segregation data, and can be assisted by functional analysis. The inclusion of functional data can be challenging, depending on the number of benign and pathogenic variants available for benchmarking assays. Glucokinase is the rate-limiting step for glucose metabolism in the pancreatic beta-cell and governs the threshold for glucose-stimulated insulin release. Loss-of-function alleles in the glucokinase (GCK) gene are a cause of stable fasting hyperglycemia from birth and/or diabetes. In this study, we functionally characterized 25 variants identified during diagnostic testing or in exome sequencing studies. We assessed their kinetic characteristics, stability, and interaction with pharmacological and physiological regulators. We integrated our functional data with existing data from the ClinGen Monogenic Diabetes Variant Curation Expert Review panel using a gene-specific framework to assist variant classification. We show how functional evidence can aid variant classification, thus enabling diagnostic certainty.


  • Open Access

    Psychological state at the time of psychiatric genetic counseling impacts patient empowerment: A pre–post analysis

    by Rachel Gore Moses, Colleen Jodarski, Michael Setzer, Katie L. Lewis, Jia Yan, Sophie Byers, Mani Yavi, Elizabeth D. Ballard, Magdalena Walkiewicz, Carlos A. Zarate, et al.

    Psychiatric genetic counseling (GC) has been associated with patient‐reported increases in empowerment (perceived control, emotional regulation, and hope). We sought to evaluate the extent to which patients' psychological state at the time of GC is related to changes in empowerment. Participants with a history of major depressive disorder and/or bipolar disorder that had been refractory to treatment underwent psychiatric GC remotely from 2022 to 2023. GC was performed by four genetic counselors and included discussion of perceived causes of illness, multifactorial inheritance, and protective factors. Empowerment, depression, and anxiety were measured immediately prior to GC via online survey by the GCOS‐16, PHQ‐9, and GAD‐7, respectively. Empowerment was re‐assessed 2 weeks later. In total, 66/161 (41.0%) invited individuals completed both the baseline and follow‐up surveys. Participants completing both surveys were 54.6% female, 84.8% white, and ranged in age from 22 to 78 years (mean = 54.8 years). Overall, a significant change in mean empowerment was not observed (p = 0.38); however, there were moderating effects by baseline psychological state. A multiple linear regression model incorporating PHQ‐9, GAD‐7 and baseline GCOS‐16 score predicted change in empowerment with a large effect (F = 5.49, R2 = 0.21, p < 0.01). A higher score on the PHQ‐9 was associated with decreases in empowerment from pre to post GC. Higher scores on the GAD‐7 and lower baseline GCOS‐16 scores were associated with increases in empowerment. Further, two‐way ANOVA was conducted to assess change in empowerment between subgroups based on the level of anxiety and depression. Those with low depression and high anxiety reported significant increases in empowerment (F = 6.64, p = 0.01). These findings suggest that psychiatric GC may be especially helpful to individuals experiencing anxiety and low baseline empowerment. Alternative approaches may be needed to best meet the needs of those experiencing significant depression.


  • Open Access

    Correction to: Understanding the phenotypic spectrum and family experiences of XYY syndrome: Important considerations for genetic counseling

    by Colleen Jodarski, Rylee Duncan, Erin Torres, Rachel Gore, Armin Raznahan, Morgan Similuk


  • Open Access

    Understanding the phenotypic spectrum and family experiences of XYY syndrome: Important considerations for genetic counseling

    by Colleen Jodarski, Rylee Duncan, Erin Torres, Rachel Gore, Armin Raznahan, Morgan Similuk

    XYY syndrome is characterized by a variable neurodevelopmental phenotype, with features including developmental delays, cognitive impairments, and an increased risk for mental health conditions. There are two recent developments that have primarily motivated this review. The first is the increased use of non-invasive prenatal screening (NIPS), which will likely result in more individuals being diagnosed with XYY prenatally. As such, health care providers (HCPs) both within genetics and outside of the specialty are more likely to encounter this diagnosis in the future. The second is advances in the understanding of the phenotypic variability of XYY through biobank and deep phenotyping efforts. As the phenotypic spectrum of XYY syndrome continues to expand, families will face greater uncertainty when receiving this diagnosis. Given both of these developments, HCPs will need to have up-to-date and accurate information about XYY to better counsel families. Furthermore, the ability to employ effective counseling techniques, such as anticipatory guidance, will aid in supporting and guiding families through the diagnostic journey. This review aims to provide insight on the neurodevelopmental and psychosocial aspects of XYY syndrome by discussing current research and borrowing from the relevant psychosocial literature of other genetic conditions. In this way, we hope to equip HCPs with the ultimate goal of improving the care and support provided to individuals with XYY and their families.